Escitalopram for the treatment of major depression and anxiety disorders

HÖSCHL, Cyril and Jaromír ŠVESTKA. Escitalopram for the treatment of major depression and anxiety disorders. Expert Rev. Neurotherapeutics. 2008, vol. 8, No 4, p. 537-552. ISSN 1473-7175.

Basic information

Original name

Escitalopram for the treatment of major depression and anxiety disorders

Name in Czech

Escitalopram při léčbě velkých depresí a úzkostných poruch

Authors

HÖSCHL, Cyril and Jaromír ŠVESTKA

Edition

Expert Rev. Neurotherapeutics, 2008, 1473-7175

---

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30000 3. Medical and Health Sciences

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

Organization unit

Faculty of Medicine

Keywords in English

escitalopram; major depression; anxiety disorders

Tags

anxiety disorders, escitalopram, major depression

Tags

International impact, Reviewed

---

Abstract

V originále

Escitalopram is the S-enantiomer of the selective serotonin reuptake inhibitor (SSRI) citalopram, which contains equal amounts of the S- and R-forms in a racemic mixture. Escitalopram is the most selective SSRI, with almost no significant affinity to other tested receptors. It has been demonstrated that it is escitalopram that carries the therapeutic potential of citalopram, and has statistically superior and clinically relevant properties compared with citalopram. Escitalopram is at least as effective in the treatment of depression and anxiety as other SSRIs, as well as venlafaxine, bupropion and duloxetine. Owing to multiple metabolic degrading pathways, the clinically relevant interactions of escitalopram with other drugs are minimal. Compared with other antidepressants, escitalopram is generally better tolerated, its onset of action is relatively fast, and its use may have cost–effectiveness and cost–utility advantages. Escitalopram is an effective first-line option in the management of patients with major depression, including severe forms, and various anxiety disorders.

In Czech

Escitalopram se řadí mezi inhibitory se zpětným vychytáváním serotoninu (SSRI).